Km. English et al., Low-dose transdermal testosterone therapy improves angina threshold in menwith chronic stable angina - A randomized, double-blind, placebo-controlled study, CIRCULATION, 102(16), 2000, pp. 1906-1911
Citations number
17
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background-Experimental studies suggest that androgens induce coronary vaso
dilatation. We performed this pilot project to examine the clinical effects
of long-term low-dose androgens in men with angina.
Methods and Results-Forty-six men with stable angina completed a 2-week, si
ngle-blind placebo run-in, followed by double-blind randomization to 5 mg t
estosterone daily by transdermal patch or matching placebo for 12 weeks, in
addition to their current medication. Time to l-mm ST-segment depression o
n treadmill exercise testing and hormone levels were measured and quality o
f life was assessed by SF-36 at baseline and after 4 and 12 weeks of treatm
ent. Active treatment resulted in a 2-fold increase in androgen levels and
an increase in time to l-mm ST-segment depression from (mean+/-SEM) 309+/-2
7 seconds at baseline to 343+/-26 seconds after 4 weeks and to 361+/-22 sec
onds after 12 weeks. This change was statistically significant compared wit
h that seen in the placebo group (from 266+/-25 seconds at baseline to 284/-23 seconds after 4 weeks and to 292+/-24 seconds after 12 weeks; P=0.02 b
etween the 2 groups by ANCOVA). The magnitude of the response was greater i
n those with lower baseline levels of bioavailable testosterone (r=-0.455,
P<0.05). There were no significant changes in prostate specific antigen, he
moglobin, lipids, or coagulation profiles during the study. There were sign
ificant improvements in pain perception (P=0.026) and role limitation resul
ting from physical problems (P=0.024) in the testosterone-treated group.
Conclusions-Low-dose supplemental testosterone treatment in men with chroni
c stable angina reduces exercise-induced myocardial ischemia.